Information Provided By:
Fly News Breaks for November 18, 2019
INFI
Nov 18, 2019 | 09:53 EDT
B. Riley FBR analyst Andrew D'Silva resumed coverage of Infinity Pharmaceuticals with a Buy rating and $3.50 price target. Under a prior analyst the firm had a Buy rating on the shares with a $4.50 price target.
News For INFI From the Last 2 Days
There are no results for your query INFI